Futu Morning News | Official announcement! Trump nominates Benset to serve as usa Secretary of the Treasury; Goldman Sachs is bullish on US stocks: the s&p 500 will rise to 7000 points.
Goldman Sachs 2025 csi commodity equity index outlook: Long gold is the "Top Trade", oil & gas prices may see a "temporary uptrend"; USA PMI in November hit the fastest level since April 2022, factories increase purchases of imported inputs; USA election settled, consumer confidence lower than expected, long-term inflation expectations breaking through the range top.
WHO Extends Mpox Emergency; Canada Reports First Clade I Case
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
Merck Recommends Rejection Of TRC Capital's "Mini-Tender" Offer To Purchase Up To 1M Shares Of Common Stock At $96.38 Per Share
On CNBC, Jim Lebenthal Announced Bought More AbbVie; Bought More Cisco Systems
Sanofi Becomes Latest Drugmaker to Challenge HHS Over 340B Drug-discount Program
This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Dividend Roundup: General Mills, Halliburton, Johnson & Johnson, Coca-Cola, and Others
AbbVie Analyst Ratings
Novo Nordisk Said to Have Contracted Ypsomed to Make Next Gen Obesity Drug's Pens
Zevra Niemann-Pick Disease Type C Drug Miplyffa Now Available
Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are...
Shares Of Hims & Hers Health See Volume; Traders Circulate Court Filing Regarding Shortage Of Lilly's Tirzepatide Shortage, Parties Agree To Maintain Stay As Ordered By Court In October 2024, With Joint Status Report Due By December 19, 2024, Or...
Hims & Hers Closes up 10% as Lilly Tirzepatide Compounding Dispute Resolution Delayed
Optimism Over Global Healthcare Sector Rises: Jefferies
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Citi Research's U.S. Equity Strategy Large-Cap Recommendation List
Pyxis Stock Craters 46% Amid Phase 1 Data, William Blair Downgrade
Price Over Earnings Overview: Johnson & Johnson